HC Wainwright Weighs in on Longeveron FY2027 Earnings

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Longeveron in a research note issued to investors on Monday, May 4th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.49) per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($0.62) per share.

Longeveron (NASDAQ:LGVN) last posted its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.20. The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.11 million. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%.

LGVN has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Wall Street Zen lowered Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Longeveron Trading Up 1.4%

Shares of LGVN stock opened at $0.86 on Tuesday. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.03. Longeveron has a twelve month low of $0.48 and a twelve month high of $1.80. The company’s 50-day moving average price is $0.89 and its 200-day moving average price is $0.72. The stock has a market cap of $20.08 million, a price-to-earnings ratio of -0.67 and a beta of -0.31.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.